Zacks: Brokerages Anticipate Pieris Pharmaceuticals Inc (NASDAQ:PIRS) Will Post Earnings of -$0.21 Per Share

Analysts forecast that Pieris Pharmaceuticals Inc (NASDAQ:PIRS) will announce ($0.21) earnings per share for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Pieris Pharmaceuticals’ earnings. The highest EPS estimate is ($0.18) and the lowest is ($0.24). The firm is scheduled to announce its next earnings report on Thursday, August 8th.

On average, analysts expect that Pieris Pharmaceuticals will report full year earnings of ($0.85) per share for the current year, with EPS estimates ranging from ($0.98) to ($0.78). For the next year, analysts forecast that the business will post earnings of ($1.01) per share, with EPS estimates ranging from ($1.37) to ($0.58). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Pieris Pharmaceuticals.

Pieris Pharmaceuticals (NASDAQ:PIRS) last issued its earnings results on Friday, May 10th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.02). Pieris Pharmaceuticals had a negative net margin of 84.75% and a negative return on equity of 64.64%. The firm had revenue of $8.55 million during the quarter, compared to analyst estimates of $7.85 million.

Several research analysts recently commented on the company. HC Wainwright set a $7.00 price target on Pieris Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, May 23rd. Cowen reiterated a “buy” rating on shares of Pieris Pharmaceuticals in a research note on Monday, May 13th. Zacks Investment Research upgraded Pieris Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a research note on Thursday, March 21st. Finally, ValuEngine upgraded Pieris Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, April 5th. Two analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $5.08.

Shares of PIRS opened at $4.70 on Thursday. The stock’s 50-day moving average is $4.13. Pieris Pharmaceuticals has a 12 month low of $2.39 and a 12 month high of $6.55.

A number of institutional investors have recently made changes to their positions in PIRS. SG Americas Securities LLC bought a new stake in Pieris Pharmaceuticals in the fourth quarter valued at about $36,000. BNP Paribas Arbitrage SA bought a new stake in Pieris Pharmaceuticals in the first quarter valued at about $36,000. Prudential Financial Inc. bought a new stake in Pieris Pharmaceuticals in the fourth quarter valued at about $43,000. Alambic Investment Management L.P. bought a new stake in Pieris Pharmaceuticals in the fourth quarter valued at about $59,000. Finally, D. E. Shaw & Co. Inc. increased its holdings in Pieris Pharmaceuticals by 107.0% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 49,904 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 25,794 shares during the last quarter. 59.70% of the stock is owned by hedge funds and other institutional investors.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Recommended Story: How to trade on quiet period expirations

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.